Table 2 Use of combination oral contraceptive (OC) preparations among control subjects

From: Hormonal content and potency of oral contraceptives and breast cancer risk among young women

Oestrogen/progestin content

Controls

Year of first OC use

Age at interview (y)

Age at first OC use (y)

Months of use

     

Any OC

Specified OC

Any OC use

1086 (100%)

1972

38.5 (4.46)

19.9 (3.21)

68.1 (52.6)

 

Potency

      

 High progestin/high oestrogen

130 (12%)

1969

40.6 (2.88)

19.1 (2.54)

72.9 (51.4)

58.5 (41.0)

 Low progestin/high oestrogen

270 (25%)

1970

39.7 (3.67)

19.4 (2.65)

74.0 (55.1)

59.3 (45.1)

 High progestin/low oestrogen

193 (18%)

1972

39.0 (3.46)

19.8 (3.08)

80.0 (53.5)

62.1 (43.3)

 Low progestin/low oestrogen

546 (50%)

1973

36.7 (4.81)

20.0 (3.45)

79.9 (56.8)

67.9 (49.7)

Oestrogen content and dose

      

 Mestranol

      

>100 μg

212 (20%)

1969

40.6 (3.04)

19.0 (2.60)

72.0 (52.8)

57.6 (42.8)

51–99 μg

141 (13%)

1971

39.1 (3.78)

19.6 (2.79)

75.9 (56.2)

58.3 (40.5)

50 μg

242 (22%)

1973

37.7 (4.05)

19.9 (3.23)

77.2 (52.6)

63.7 (45.2)

 Ethinyl oestradiol

      

>35 μg

247 (23%)

1972

38.4 (4.29)

20.0 (3.26)

80.1 (55.0)

62.6 (43.9)

35 μg

354 (33%)

1974

35.9 (5.03)

19.8 (3.45)

84.2 (59.2)

67.0 (48.5)

Progestin content

      

 Dimethisterone

3 (<1%)

1966

42.3 (1.15)

18.0 (1.73)

75.3 (73.1)

70.2 (78.7)

 Chlormadinone acetate

17 (2%)

1966

42.5 (1.62)

19.2 (1.55)

66.9 (65.4)

41.5 (41.5)

 Norethynodrel

29 (3%)

1969

40.6 (3.76)

19.0 (3.16)

64.1 (51.6)

45.3 (42.2)

 Ethinyl diacetate

180 (17%)

1971

39.6 (3.44)

19.3 (2.83)

73.0 (52.1)

63.9 (48.1)

 Norethindrone

663 (61%)

1972

38.0 (4.65)

19.8 (3.23)

72.5 (54.4)

66.1 (50.9)

 Norethindrone acetate

70 (6%)

1972

38.2 (3.81)

20.0 (3.24)

81.2 (55.3)

70.7 (48.6)

 Norgestrel

247 (23%)

1972

37.6 (4.38)

19.5 (2.93)

83.4 (55.1)

65.4 (46.4)

 Levonorgestrel

54 (5%)

1978

33.4 (5.26)

20.8 (4.21)

75.4 (48.6)

55.7 (36.8)

  1. Note: With the exception of median year of first oral contraceptive use, this table presents unadjusted means (s.d.) for control subjects who used oral contraceptives for a minimum of 6 months. Oestrogen/progestin categories are not mutually exclusive. For example, a woman who used both mestranol and ethinyl oestradiol preparations is counted in both categories.